Show Summary Details
Page of

Pathology of bladder and upper urinary tract tumours 

Pathology of bladder and upper urinary tract tumours
Chapter:
Pathology of bladder and upper urinary tract tumours
Author(s):

Simone Bertz

, and Arndt Hartmann

DOI:
10.1093/med/9780199659579.003.0072
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 25 June 2019

Bladder cancer is the most common malignant tumour of the urinary tract, with approximately 386,000 new cases worldwide per year, and is the fifth most common cancer in humans. Mortality rates range between 1.1 per 100,000 for women to 4 per 100,000 in men. Most bladder and urinary tract cancers are urothelial carcinoma. The remainder are squamous cell carcinoma (5%), adenocarcinoma (<5%) and other rare tumours (<1%). Around 5–10% of urothelial carcinoma are found in the upper urinary tract. Unlike the majority of malignant tumours in other anatomical sites, most urothelial carcinoma have a favourable prognosis. In patients with these tumours, long-term follow-up is crucial but costly (making bladder cancer one of the most expensive to manage). The current WHO classification system of 2004 reflects these molecular and clinical features by the definition of distinct categories for low and high-grade flat or papillary lesions.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.